Literature DB >> 28567405

Applying a mobile survey tool for assessing lymphatic filariasis morbidity in Mtwara Municipal Council of Tanzania.

Upendo J Mwingira1,2, Philip Downs3, Cecilia Uisso1, Maria Chikawe1,2, Matthieu Sauvage-Mar4, Mwelecele N Malecela2, Kathryn Crowley3, Jeremiah M Ngondi5.   

Abstract

BACKGROUND: A number of methods have been used to estimate lymphatic filariasis (LF) morbidity, including: routine programmatic data, cluster random surveys and the "town crier" method. Currently, few accurate data exist on the global LF morbidity burden in Tanzania. We aimed to estimate prevalence of lymphedema and hydrocele in Mtwara Municipal Council using mobile phone based survey.
METHODS: A cross-sectional survey was conducted among adults of Mtwara Municipal council with access to mobile phones. A sample size of at least 384 completed surveys was required to estimate prevalence of lymphedema (both males and females) and hydrocele (males only) morbidity of 50% within a 5% error margin given a 5% level of significance and 95% confidence level. Eligible mobile phone users received a short message text (SMS) requesting consent to participate in the survey. A total of 10 questions were administered via interactive SMS through the GeoPoll, a survey platform developed by Mobile Accord (www.geopoll.com).
RESULTS: The survey was completed over a period of 4 days. A total of 8,759 surveys were sent to mobile phone subscribers of whom 1,330 (15.2%) opted-in to complete the survey. A total of 492 (37.0% of those opted-in, 384 male and 108 female) people completed the survey. Lymphedema and hydrocele signs were reported by 20.9% (95% CI, 17.4-24.8) and 20.6% (95% CI, 16.6-25.0) of respondents, respectively. Majority of hydrocele patients (59.5%) and 46.6% of lymphedema patients reported having sought treatment. The proportion of patients reporting similar symptoms among friends and relatives was 66.0% and 70.9% for lymphedema and hydrocele, respectively.
CONCLUSIONS: The findings suggest that mobile phone based surveys are a practical approach of undertaking morbidity surveys. While further surveys are needed to verify the findings, this approach can be expected to encourage identification of lymphedema and hydrocele morbidity at community level and provide evidence where further morbidity surveys are warranted.

Entities:  

Keywords:  GeoPoll surveys; Mtwara; Tanzania; hydrocele; lymphatic filariasis (LF) morbidity; lymphedema

Year:  2017        PMID: 28567405      PMCID: PMC5427189          DOI: 10.21037/mhealth.2017.03.01

Source DB:  PubMed          Journal:  Mhealth        ISSN: 2306-9740


  7 in total

Review 1.  Re-assessing the global prevalence and distribution of lymphatic filariasis.

Authors:  E Michael; D A Bundy; B T Grenfell
Journal:  Parasitology       Date:  1996-04       Impact factor: 3.234

2.  Collecting baseline information for national morbidity alleviation programs: different methods to estimate lymphatic filariasis morbidity prevalence.

Authors:  Els Mathieu; Josef Amann; Abel Eigege; Frank Richards; Yao Sodahlon
Journal:  Am J Trop Med Hyg       Date:  2008-01       Impact factor: 2.345

Review 3.  SMS for disease control in developing countries: a systematic review of mobile health applications.

Authors:  Carole Déglise; L Suzanne Suggs; Peter Odermatt
Journal:  J Telemed Telecare       Date:  2012-07-23       Impact factor: 6.184

4.  Developing a community-led SMS reporting tool for the rapid assessment of lymphatic filariasis morbidity burden: case studies from Malawi and Ghana.

Authors:  Michelle C Stanton; Square Z Mkwanda; Alexander Y Debrah; Linda Batsa; Nana-Kwadwo Biritwum; Achim Hoerauf; Matthew Cliffe; Abigail Best; Andrew Molineux; Louise A Kelly-Hope
Journal:  BMC Infect Dis       Date:  2015-05-16       Impact factor: 3.090

5.  Lymphatic filariasis control in Tanga Region, Tanzania: status after eight rounds of mass drug administration.

Authors:  Paul E Simonsen; Yahya A Derua; Stephen M Magesa; Erling M Pedersen; Anna-Sofie Stensgaard; Mwelecele N Malecela; William N Kisinza
Journal:  Parasit Vectors       Date:  2014-11-12       Impact factor: 3.876

6.  Lymphatic filariasis control in Tanzania: effect of six rounds of mass drug administration with ivermectin and albendazole on infection and transmission.

Authors:  Paul E Simonsen; Yahya A Derua; William N Kisinza; Stephen M Magesa; Mwele N Malecela; Erling M Pedersen
Journal:  BMC Infect Dis       Date:  2013-07-21       Impact factor: 3.090

7.  The Global Trachoma Mapping Project: Methodology of a 34-Country Population-Based Study.

Authors:  Anthony W Solomon; Alexandre L Pavluck; Paul Courtright; Agatha Aboe; Liknaw Adamu; Wondu Alemayehu; Menbere Alemu; Neal D E Alexander; Amir Bedri Kello; Berhanu Bero; Simon J Brooker; Brian K Chu; Michael Dejene; Paul M Emerson; Rebecca M Flueckiger; Solomon Gadisa; Katherine Gass; Teshome Gebre; Zelalem Habtamu; Erik Harvey; Dominic Haslam; Jonathan D King; Richard Le Mesurier; Susan Lewallen; Thomas M Lietman; Chad MacArthur; Silvio P Mariotti; Anna Massey; Els Mathieu; Addis Mekasha; Tom Millar; Caleb Mpyet; Beatriz E Muñoz; Jeremiah Ngondi; Stephanie Ogden; Joseph Pearce; Virginia Sarah; Alemayehu Sisay; Jennifer L Smith; Hugh R Taylor; Jo Thomson; Sheila K West; Rebecca Willis; Simon Bush; Danny Haddad; Allen Foster
Journal:  Ophthalmic Epidemiol       Date:  2015       Impact factor: 1.648

  7 in total
  2 in total

1.  Mapping the global distribution of Buruli ulcer: a systematic review with evidence consensus.

Authors:  Hope Simpson; Kebede Deribe; Earnest Njih Tabah; Adebayo Peters; Issaka Maman; Michael Frimpong; Edwin Ampadu; Richard Phillips; Paul Saunderson; Rachel L Pullan; Jorge Cano
Journal:  Lancet Glob Health       Date:  2019-07       Impact factor: 26.763

Review 2.  Mobile Health Strategies to Tackle Skin Neglected Tropical Diseases With Recommendations From Innovative Experiences: Systematic Review.

Authors:  Carme Carrion; Noemí Robles; Oriol Sola-Morales; Marta Aymerich; Jose Antonio Ruiz Postigo
Journal:  JMIR Mhealth Uhealth       Date:  2020-12-31       Impact factor: 4.773

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.